F-18-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma

Background: Bone disease in multiple myeloma is characterized by reduced bone formation. The gold standard of bone formation is the mineral apposition rate (MAR), an invasive technique reflecting bone formation at a single site. We compared F-18-fluoride-PET with the MAR in myeloma patients. Methods: Bone formation was measured before and after bortezomib treatment by determination of the MAR in iliac bone marrow biopsies and the measurement of F-18-uptake. Results: The inter-and intra-individual variations in F-18-uptake (SUVA50%) were pronounced as 33.50 (range 4.42 to 37.92) and 27.18 (range 4.00 to 31.18), respectively. A significant correlation between the MAR and F-18-uptake was found (r = 0.80, p = 0.017). There was a heterogeneous response after treatment varying from -2.20 to 4.53. Conclusions: Iliac F-18-uptake was associated with the local MAR in myeloma patients. Furthermore, F-18-fluoride-PET demonstrated the heterogeneity of in vivo bone formation, enabling monitoring during treatment

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on frailty level. Clinical scores such as the International Myeloma Working Group frailty index (IMWG-FI) classify patients in categories ‘fit’, ‘intermediate-fit’ or ‘frail’. As disease and treatment burden can change over time, frailty can improve but also deteriorate during treatment. However, data are scarce and the effects on clinical outcome are largely unknown. To address this, we prospectively investigated the dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in the HOVON 143 study

Dynamic Frailty Status Enables Better Prediction of Survival Probability - Results of the HOVON 143 Study

The clinical outcome of non-transplant eligible patients with newly diagnosed Multiple Myeloma (NDMM) is heterogeneous, largely depending on frailty level. Clinical scores such as the International Myeloma Working Group frailty index (IMWG-FI) classify patients in categories ‘fit’, ‘intermediate-fit’ or ‘frail’. As disease and treatment burden can change over time, frailty can improve but also deteriorate during treatment. However, data are scarce and the effects on clinical outcome are largely unknown. To address this, we prospectively investigated the dynamics of frailty scores and impact on clinical outcome of non-transplant eligible patients with NDMM (NTE-NDMM) included in the HOVON 143 study